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The Drosophila homolog of cAMP-response element-
binding protein (CREB), dCREB2, exists with serine 231,
equivalent to mammalian serine 133, in a predominantly
phosphorylated state. Thus, unlike the mammalian pro-
tein, the primary regulation of dCREB2 may occur at a
different step from serine 231 phosphorylation. Al-
though bacterially expressed dCREB2 bound cAMP-re-
sponse element sites, protein from Drosophila extracts
was unable to do so unless treated with phosphatase.
Phosphorylation of recombinant protein by casein ki-
nase (CK) I or II, but not calcium-calmodulin kinase II or
protein kinase A, inhibited DNA binding. Up to four
conserved CK sites likely to be phosphorylated in vivo
were responsible for this effect, and these sites were
phosphorylated by a kinase present in Drosophila cell
extracts that biochemically resembles CKII. We propose
that the relative importance of different signaling path-
ways in regulating CREB activity may differ between
Drosophila and mammals. In Drosophila, the dephos-
phorylation of CK sites appears to be the major regula-
tory step, while phosphorylation of serine 231 is neces-
sary but secondary.
The cAMP-response element-binding protein (CREB)1 has
been implicated in a large number of cellular and physiological
processes (1). It is a transcription factor that binds to CRE sites
and is involved in adaptive responses to a wide variety of
stimuli, including neuronal activity, memory formation, drugs
of abuse, growth factors, hormones, and peptide signaling.
These responses contribute to its transcriptional role in circa-
dian biology, the stress response, neuritogenesis, developmen-
tal plasticity, and memory formation (2–5).
In mammals, the CREB family consists of three different
genes: CREB, CREM, and ATF-1 (1). Although their protein
products are very similar, minor sequence differences exist,
and the physiological distinctions between them are not en-
tirely clear. Genetic knock-out studies indicate that these genes
probably have similar functions since loss-of-function muta-
tions in individual genes result in compensatory changes in
expression of the others (6, 7).
Sequence alignment of CREB genes from many species iden-
tifies two regions of the protein that are highly conserved (1), a
basic region-leucine zipper structural motif involved in dimer-
ization and DNA binding and a 60-amino acid kinase-inducible
domain (KID) (Fig. 1). CREB activity is regulated by phospho-
rylation of sites within the KID. Notably phosphorylation of a
protein kinase A (PKA) site at serine 133 (Ser-133) allows
CREB to interact with the co-activator CREB-binding protein,
which in turn activates transcription by recruiting RNA polym-
erase II complexes to CRE-containing promoters and by acety-
lating histones (8–12). A variety of other kinases, including the
extracellular signal-regulated kinase/mitogen-activated pro-
tein kinase/ribosomal S6 kinase cascade, protein kinase C, and
calcium/calmodulin-dependent kinases (CaMKs), have also
been shown to target Ser-133 (13).
Other regulatory sites within the KID include Ser-129 and
Ser-142 (14). Ser-129 is believed to be a substrate for glycogen
synthase kinase 3. Phosphorylation of this site occurs only after
phosphorylation of Ser-133 and can function to reduce DNA
binding of CREB (15, 16). Ser-142 can be phosphorylated by
CaMKII and is implicated in either inhibiting CREB activity
(17) or stimulating CREB-binding protein-independent CREB
activation (18). In addition, serine residues thought to be tar-
gets for casein kinases (CKs) are found at residues 108, 111,
114, 117, and 121.
The Drosophila CREB homolog, dCREB2, is of particular
interest since it is a critical molecule in long term memory
formation in flies. Studying its regulation may yield insights to
the regulation of memory formation. Similar to CREB from
other species, dCREB2 has a conserved KID domain (Fig. 1).
Ser-231, which is homologous to the critical mammalian Ser-
133 residue, can be phosphorylated by PKA, and a serine to
alanine mutation at this site completely abolishes activity (19).
Mammalian Ser-129 and Ser-142 are also conserved as Thr-227
and Ser-240, respectively. In addition, the CK sites are posi-
tionally conserved N-terminal to Ser-133/231 and are similarly
surrounded by acidic amino acids (20).
CKII is a ubiquitous, highly conserved serine/threonine ki-
nase (21). Currently its regulation and precise biological roles
are poorly understood, but it is essential for viability of eu-
karyotes. It has been reported to interact with the basic-leucine
zipper domains of several transcription factors, including
ATF-1 and CREB (22). In some cases, phosphorylation by CKII
has been reported to regulate binding to DNA. It is proposed
that CKII inhibits DNA binding of the c-Jun transcription
factor (23) and enhances the DNA binding properties of CREM
(24). The CK sites of CREB are phosphorylated during early S
phase in a cell cycle-dependent manner, although the role of
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this phosphorylation has not been elucidated (25). In Drosoph-
ila, CKII interacts with and phosphorylates basic-helix-loop-
helix proteins (26).
In the current study, we showed that a large proportion of
dCREB2 Ser-231 exists in a phosphorylated state. This sug-
gested to us that, in flies, an alternate regulatory mechanism
might be preferentially utilized. We propose that the CK sites
of dCREB2 may provide this mechanism by regulating DNA
binding. In support of this model, we demonstrated that phos-
phorylation of the CK sites prevents DNA binding, while de-
phosphorylation allows dCREB2 to bind. Furthermore we
showed that phosphorylation of these sites is likely to occur in
vivo and that a kinase that shares similarities to CKII is
present in Drosophila extracts and phosphorylates these sites.
Regulation of DNA binding through phosphorylation/dephos-
phorylation of these sites may be a novel mechanism of con-
trolling CREB activity separate from Ser-133 phosphorylation.
MATERIALS AND METHODS
Extract Preparation—Drosophila head extracts were made by freez-
ing flies in liquid nitrogen, isolating heads, and crushing them with a
pestle. For Western analysis, heads were crushed directly in SDS load-
ing buffer (27) and used at a concentration of 5 l/head. For extracts
used in electrophoretic mobility shift assays (EMSAs), crushed heads
were extracted by addition of 3 l/head cold homogenization buffer (15
mM Hepes, pH 7.5, 10 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 0.5 mM
EGTA, 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride).
Extracts were centrifuged twice at 14,000  g to remove debris. An
equal volume of 2 HEMG (200 mM KCl, 40 mM Hepes, pH 7.5, 20 mM
MgCl2, 0.2 mM EDTA, 20% glycerol, 1 mM dithiothreitol, and 1 mM
phenylmethylsulfonyl fluoride) was added, and protein concentrations
were determined using the Bradford assay. Extracts containing 100 mM
EDTA were made as above except that the EDTA concentration was
raised to 100 mM in all solutions used. For extracts fractionated using
phosphocellulose, the 2 HEMG was supplemented with 1 M NaCl to
make a final extract concentration of 500 mM NaCl.
Schneider-2 (S2) cells were grown and passaged as described previ-
ously (28). Extracts were made by resuspending cells in 3 times their
packed cell volume of homogenization buffer and lysing by freeze/
thawing in liquid nitrogen three times in rapid succession. Debris were
removed from extracts by centrifugation, and an equal volume of 2
HEMG was added. Protein concentrations were determined using the
Bradford assay.
For phosphocellulose fractionation of extracts, cellulose phosphate
P-11 was prepared as recommended by the manufacturer (Whatman
BioSystems Ltd.) and equilibrated in 1 HEMG with 500 mM NaCl.
Head extracts were added to the phosphocellulose at a ratio of 100 l of
extract to 50 l of phosphocellulose and incubated at 4 °C for 1 h on a
rotator. Mixtures were centrifuged at 1000  g for 10 min to separate a
supernatant (flow-through) fraction from the pellet fraction. After
washing with HEMG containing 500 mM NaCl, the pellet fraction was
mixed with 0.5 times the original extract volume of HEMG with 1.5 M
NaCl. Mixtures were rotated at 4 °C for 1 h, and then the 1.5 M NaCl
solution was collected (elution fraction). Both flow-through and elution
fractions were dialyzed against 1 HEMG.
Mutagenesis, Plasmid Construction, Purification of Recombinant
dCREB2 Protein, and Generation of Transgenic Flies—In vitro oligonu-
cleotide-directed mutagenesis was performed on pJY386 (20), a cDNA of
the dCREB2-b isoform originally isolated from a Drosophila head cDNA
library and subcloned into Bluescript pKS (Stratagene). The muta-
tions that were made were: S231A (TCG codon changed to GCG),
(CK1–4)A, S210A (AGC changed to GCC), S213A (AGT changed to
GCT), S215A (TCG changed to GCC), S219A (TCC changed to GCC),
and S240A (AGC changed to GCC). All derivatives were sequenced on
both strands. These were subcloned into pET30C to express protein in
bacteria and into CaSpeR-HS to make transgenic flies expressing the
open reading frames under the control of the heat shock promoter.
Plasmid names are as follows: pJY1048  S231A in pBluescript,
pJY1060  S231A in pET30C, pJY1056  S231A in CaSpeR-HS,
pJY1049 (CK1–4)A in pBluescript, pJY1061 (CK1–4)A in pET30C,
pJY1057 (CK1–4)A in CaSpeR-HS, pJY1051 S240A in pBluescript,
pJY1062  S240A in pET30C, and pJY1058  S240A in CaSpeR-HS.
Growth of bacteria, induction, and purification of proteins on nickel-
nitrilotriacetic acid-agarose columns was done according to the manu-
facturer’s recommendations (Qiagen). Transgenic flies were produced
using standard techniques. Transgenes were induced using a 30-min
temperature shift from 25 °C to 37 °C followed by 3 h at 25 °C prior to
extract preparation.
Kinase and Phosphatase Treatment—CKI, CKII, PKA, CaMKII, and
 protein phosphatase were purchased from New England Biolabs.
Phosphorylation and phosphatase reactions were performed as recom-
mended by the manufacturer. For gel shift phosphatase treatments, 10
g of extract or 6 ng of recombinant dCREB2 were dephosphorylated in
a total volume of 10 l using 200 units of phosphatase. Recombinant
dCREB2 was phosphorylated using S2 extract by mixing 10 ng of
recombinant protein with 20 g of extract in a total volume of 10 l of
20 mM Tris-HCl, 50 mM KCl, 10 mM MgCl2, and 100 M ATP. Mixtures
were incubated at room temperature for 1 h. For 5,6-dichloro-1--D-
ribofuranosylbenzimidazole (DRB) inhibition experiments, DRB was
added at the indicated concentrations.
EMSAs—Sequences of the 3xCRE double-stranded oligonucleotide
probe and the mutated 3xCRE oligonucleotide have been described
previously (20). 200 ng of probe were radiolabeled using polynucleotide
kinase in the presence of 100 Ci of [-32P]ATP as recommended by the
manufacturer (New England Biolabs). Probe (4–5  105 cpm) was
incubated with 5 g of Drosophila extract, 4 g of mouse extract, or 3 ng
of recombinant dCREB2 for each gel shift experiment. Incubations were
carried out in a volume of 10 l at room temperature for 1 h in 12 mM
Hepes, pH 7.9, 4 mM Tris-Cl, pH 7.9, 1 mM EDTA, 12% glycerol, 1 mM
dithiothreitol, 5 mM MgCl2, 60 mM KCl, 1 mg/ml bovine serum albumin,
and 0.4 mg/ml poly(dI-dC). Mixtures were then run on a 4% acrylamide
(acryl:bis  80:1), Tris-glycine (380 mM glycine, 50 mM Tris base, 2 mM
EDTA, 3.6 mM MgCl2, and 1% glycerol) gel, transferred to Whatman No.
3MM paper, and exposed to film. For antibody supershift experiments,
0.5 l of anti-mouse CREB antibody (New England Biolabs) or anti-
dCREB2 antibody (3) were added to each binding reaction.
Peptide Analysis—Recombinant dCREB2 was phosphorylated with
S2 extract as described above except that the recombinant protein used
was between 50 ng and 1 g, and the ATP concentration was 60 pM cold
ATP and 50 Ci of [-32P]ATP. Phosphorylation reactions were sepa-
rated on a 10% SDS-polyacrylamide gel. The radiolabeled CREB band,
identified by Coomassie staining and exposing the wet gel to film, was
excised, and gel slices were extensively washed with 50% methanol,
10% acetic acid and then with 50% methanol before being lyophilized.
Slices were then treated with 1 ml of trypsin (75 mg/ml in 50 mM
NH4CO3H, pH 8.0) for 20 h at 37 °C. Supernatants from the trypsin
digestion were lyophilized, resuspended in 200 l of H2O, lyophilized,
resuspended in 100 l of 10% acetic acid, 1% pyridine, lyophilized, and
finally resuspended in 10 l of 25% acetonitrile, 7.5% acetic acid, 0.75%
pyridine. Samples were applied with phenol red tracking dye to TLC
plates and electrophoresed at 400 V at pH 3.5 until the phenol red
migrated halfway to the anode. Following electrophoresis, plates were dried
and subjected to thin layer chromatography in a solvent of 25% 1-butanol,
7.5% acetic acid, and 37.5% pyridine until the phenol red migrated close to
the top of the plate. Plates were dried and exposed to film at 80 °C with
intensifying screens or analyzed by PhosphorImager.
Denaturing Non-SDS-PAGE—Denaturing non-SDS-polyacrylamide
gels were similar to standard SDS gels (27) except that SDS was
omitted and replaced with 8 M urea in the resolving and stacking gels
and sample loading buffer. The concentration of the reducing agent
dithiothreitol in sample loading buffer was 100 mM.
Ser-231-phosphospecific Antibody—Two peptides were synthesized,
one with the sequence H-Cys-Glu-Leu-Thr-Arg-Arg-Pro-Ser-Tyr-Asn-
Lys-Ile-Phe-Thr-NH2 and another with the identical sequence but with
the serine phosphorylated. The phosphorylated peptide was conjugated
to keyhole limpet hemocyanin using an Imject Immunogen EDC conju-
gation kit (Pierce) as recommended by the manufacturer and injected
into rabbits using standard techniques (29). To purify rabbit polyclonal
serum, both phosphorylated and unphosphorylated peptides were re-
duced (Reduce-Imm reducing kit, Pierce) and cross-linked to agarose
beads in a column (AminoLink immobilization kit, Pierce). Columns
were run sequentially, and purified sera consisted of the flow-through of
the column containing unphosphorylated peptide and the elution of the
column containing the phosphorylated peptide.
RESULTS
Most dCREB2 Ser-231 Exists in a Phosphorylated Form—In
mammals, CREB activity has been correlated with Ser-133
phosphorylation, and Ser-133-phosphospecific antibody has
been used widely to identify tissues or areas where CREB has
been activated (30, 31). We wanted to quantify the total
amount of dCREB2 present in fly heads and determine the
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percentage of this protein that was phosphorylated at Ser-231,
the equivalent site to mammalian Ser-133 (Fig. 1). Recombi-
nant dCREB2-b protein (an inhibitory isoform) was purified
from bacteria and is referred to as rec-dCREB2-wt. Various
dilutions of the rec-dCREB2-wt protein and varying amounts of
Drosophila head extracts were analyzed on Western blots using
dCREB2-specific monoclonal and Ser-231-phosphospecific an-
tibodies. Fig. 2 shows that our monoclonal antibody had similar
affinity for non-phosphorylated or phosphorylated protein and
results in linearity of band intensity with protein levels in the
range tested. Using this antibody, we estimated that a single
Drosophila head contains 0.67 ng of dCREB2 protein (based
on three to five heads). An equivalent blot, probed with the
Ser-231-phosphospecific antibody, demonstrates the specificity
of the antibody since 30 ng of non-phosphorylated protein gave
no signal, while 2 ng of PKA-phosphorylated protein produced
a clear band. Similar to the monoclonal antibody, the band
intensity produced by the phosphospecific antibody varied pro-
portionally with rec-dCREB2-wt levels (Fig. 2, lower panel,
lanes 1–6). Comparison of band intensities between head ex-
tracts and recombinant protein led to an estimate of0.67–0.8
ng of Ser-231-phosphorylated dCREB2/head (based on three to
five heads). This result indicates that a large proportion, if not
all, of the dCREB2 present in Drosophila heads exists in a
Ser-231-phosphorylated state. This is a surprising result since
the majority of mammalian CREB seems to exist in a non-
phosphorylated and inactive form. Activation of mammalian
CREB critically depends upon stimulation of pathways that
lead to phosphorylation of Ser-133.
Phosphatase Treatment Unmasks dCREB2 DNA Binding Ac-
tivity—We next wanted to determine whether our identified
dCREB2 was able to bind DNA. When extracts were tested for
CRE DNA binding using EMSAs, one shifted band was de-
tected (Fig. 3A, lane 2). If the extracts were treated with 
phosphatase prior to the binding reactions, a second, slower
migrating band was observed (lane 3). The proteins in both of
these complexes bound specifically to CRE sites since excess
cold CRE, but not mutated CRE, oligonucleotides competed for
binding (lanes 5 and 6). To determine which of these two
complexes contains dCREB2, supershift studies were per-
formed using dCREB2 monoclonal antibody. As shown in Fig.
3A, lane 4, antibody was able to supershift only the phosphatase-
dependent band. The phosphatase-independent band seemed
to be unrelated to dCREB2 and was not studied further. Thus,
in Drosophila head extracts, there are at least two CRE-bind-
ing protein complexes, but only the phosphatase-dependent one
contains dCREB2 protein.
The phosphatase dependence of dCREB2 binding was not
limited to head extracts since dCREB2 from Drosophila S2 cell
extracts behaved identically (Fig. 3B). These data suggest that,
in Drosophila, the dCREB2 protein exists in a phosphorylated
state that is unable to bind DNA and that binding requires the
dephosphorylation of one or more residues.
Casein Kinase Treatment Inhibits Recombinant dCREB2
DNA Binding Activity—If Drosophila contain a kinase that
phosphorylates and inactivates dCREB2 binding activity, then
bacterially expressed dCREB2 should be free from this phos-
phorylation and able to bind DNA. As expected, rec-
dCREB2-wt was able to bind CRE sites as assayed using EMSA
(Fig. 4). Phosphorylation of the protein using CKI or CKII
severely inhibited binding (Fig. 4, left panel), while phospho-
rylation using PKA or CaMKII had only slight or negligible
effects. In all cases, the incorporation of phosphate into
dCREB2 was verified in parallel experiments using [-32P]ATP
as a phosphate source (Fig. 7 and data not shown).
One trivial explanation for the disappearance of DNA bind-
FIG. 2. Comparison of amounts of total dCREB2 and phospho-
Ser-231 dCREB2 in Drosophila heads. Varying amounts of recom-
binant dCREB2 and head extracts were subjected to PAGE and West-
ern analysis. In the row marked “rec-dCREB2-wt,” numbers refer to the
amount (in ng) of recombinant dCREB2 loaded on the gel. In the row
marked “heads,” numbers refer to the number of head equivalents
loaded. Recombinant protein was either treated () or untreated with
PKA as indicated. Western blots were probed with either monoclonal
dCREB2 antibody (dCREB2 mAb), which does not differentiate be-
tween phosphorylation states, or Ser-231-phosphospecific antibody
(Ab). Recombinant dCREB2 runs at a higher molecular weight com-
pared with endogenous dCREB2. Part of the reason for this aberrant
mobility is that recombinant dCREB2 contains extra residues encoded
in pET30C, including a His6 tag used for purification, fused onto the C
terminus of the protein.
FIG. 1. Sequence comparisons
within the kinase-inducible domains
of mammalian CREB, CREM, and
Drosophila CREB2. Ser-133/231, Ser-
142/240, Ser-129/Thr-227, and the CK
sites are underlined and numbered. Mu-
tations generated and used in this study
are indicated. “mCK” refers to mutations
created in rat CREB and used in the tis-
sue culture transfection experiments.
“CK” shows the Ser to Ala mutations pres-
ent in rec-dCREB2-CK and expressed in
hs-CREB-CK flies, “133” shows the muta-
tion present in rec-dCREB2-133 and ex-
pressed in hs-CREB-133 flies, and “142”
shows the mutation present in rec-dCREB2-
142 and expressed in hs-CREB-142.
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ing subsequent to the addition of CKI or CKII would be prote-
olysis of rec-dCREB2-wt due to the presence of contaminating
proteases in these samples. We demonstrated that this was not
the case since addition of excess phosphatase after the kinase
reactions restored binding activity (Fig. 4, right panel). This
reversal of kinase-mediated inhibition suggests that CKI and
CKII exert their effects through phosphorylation. Furthermore
the inhibition of binding was dependent on the presence of ATP
as a phosphate source during incubation with the kinase (data
not shown). Thus we propose that CKI, CKII, and/or another
kinase with similar site specificity is present in Drosophila and
prevents dCREB2 from binding to CRE sites.
Mutating Serines 210, 213, 215, and 219 Prevents Casein
Kinase II-mediated Inhibition of DNA Binding—We hypothe-
sized that the conserved CK sites in the KID of dCREB2 might
be involved in regulating binding. Thus we mutated a number
of different sites on the dCREB2-b isoform, including the CK
sites, and tested mutant recombinant protein for DNA binding
activity. rec-dCREB2-133 contains a mutation of Ser-231 to
Ala. rec-dCREB2-CK contains Ser to Ala substitutions at the
four putative CK sites located at residues 210, 213, 215, and
219. rec-dCREB2-142 is dCREB2 with residue 240 mutated to
Ala. As shown in Fig. 5, all recombinant proteins bound simi-
larly. However, only the rec-dCREB2-CK protein bound DNA
after treatment with CKII. Phosphorylation of serines corre-
sponding to mammalian residues 133 and 142 appear not to be
involved in regulating DNA binding. Treatment with excess
phosphatase after kinase treatment led to a recovery of DNA
binding.
Schneider Cell Extracts Contain a Kinase That Inhibits
Binding—Incubation of bacterially expressed dCREB2 protein
in an S2 extract inhibited DNA binding (Fig. 6, lane 3). How-
ever, when rec-dCREB2-CK was incubated, it was still able to
bind DNA (lane 4). Subsequent phosphatase treatment re-
stored DNA binding of dCREB2-wt (lanes 5 and 6). These
observations indicate that there is an active kinase present in
S2 extracts that phosphorylates dCREB2 at the CK sites and
inhibits DNA binding.
The bands present in Fig. 6, lanes 5 and 6, are somewhat
darker and broader than the bands present in lanes 1 and 2
(recombinant proteins alone). This broadening is likely due to
two separate factors. Phosphatase treatment allows not only
recombinant rec-dCREB2-wt to bind but also unmasks binding
of endogenous dCREB2 proteins present in S2 extracts (see Fig.
3B). Gel shift species containing recombinant dCREB2 mi-
grated at a position slightly higher than those containing en-
dogenous dCREB2 (see Figs. 2 and 8A), resulting in a darken-
ing and broadening of the shifted band, which now included
recombinant dCREB2, endogenous dCREB2, and possibly het-
erodimers of the two. In addition, phosphatase treatment may
have slightly enhanced binding of recombinant dCREB2 (see
Fig. 3), suggesting that the recombinant protein may be phos-
phorylated at unknown sites when expressed in bacteria.
Peptide Mapping Confirms That the Inhibitory Kinases Phos-
phorylate Casein Kinase Sites—The preceding results all indi-
cate that CKI, CKII, and S2 extracts all phosphorylate
FIG. 4. Binding to CRE sites of recombinant dCREB2 phospho-
rylated in vitro. 3 ng of purified rec-dCREB2-wt were either left
unphosphorylated (lanes 1 and 6) or phosphorylated with the indicated
kinases (lanes 2–5 and 7–10) before being mixed with CRE radiolabeled
probe and subjected to EMSA. Samples in lanes 6–10 were treated with
excess  phosphatase after kinase treatment and prior to EMSA. The
position of recombinant dCREB2 is indicated.
FIG. 3. A, CRE-binding proteins in Dro-
sophila head extracts. Head extracts from
wild type Drosophila were made as de-
scribed under “Materials and Methods.” 5
g of extract were either left untreated
(lane 2) or treated (lanes 3–6) with  phos-
phatase prior to being mixed with radio-
labeled CRE DNA probe and subjected to
EMSA. Free probe alone is shown in lane
1, supershift using dCREB2 antibody is
shown in lane 4, and oligonucleotide com-
petition experiments with wild type (wt)
and mutated (mt) CRE elements, respec-
tively, are shown in lanes 5 and 6. B,
CRE-binding proteins in Schneider-2 cell
extracts. 5 g of S2 extract were either
treated (lanes 1 and 2) with  phospha-
tase or left untreated (lane 3), mixed with
CRE probe, and subjected to EMSA. Su-
pershift with dCREB2 antibody is shown
in lane 1. mAb, monoclonal antibody.
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dCREB2 and prevent DNA binding. Furthermore they suggest
that the putative CK sites play important roles in this regula-
tion of binding. To verify the similarities between the three
kinases and their relation to the CK sites, we performed pep-
tide mapping experiments.
rec-dCREB2-wt protein was phosphorylated in vitro using
PKA, CaMKII, CKI, CKII, and S2 extracts in the presence of
[-32P]ATP (Fig. 7A and data not shown). Phosphorylated prod-
ucts were subjected to PAGE, and the radiolabeled protein
band was purified and digested with trypsin. Resultant pep-
tides were separated in two dimensions using isoelectric focus-
ing and thin layer chromatography. As shown in Fig. 7B, CKI,
CKII, and the S2 extract all phosphorylated a common peptide
or peptides (labeled B), while PKA and CaMKII phosphoryl-
ated a different peptide (labeled A), which presumably contains
Ser-133 and Ser-142.
To confirm the relationship between peptide B and the pu-
tative CK sites, rec-dCREB2-CK as well as rec-dCREB2-wt was
used as a substrate for the kinase in S2 extracts. As seen in Fig.
7C, peptide B was phosphorylated when the substrate was
rec-dCREB2-wt but remained unphosphorylated when the sub-
strate was rec-dCREB2-CK. Taken together, these results pro-
vide strong supporting evidence that the kinases that inhibit
dCREB2 binding function by phosphorylating the sites that are
mutated in CREB-CK.
The Kinase in Schneider-2 Cell Extracts Shares Some Prop-
erties with Casein Kinase II—We were interested in character-
izing the kinase in S2 extracts to determine whether it was
more similar to CKI or to CKII. CKII is known to bind to
phosphocellulose at high ionic strengths (0.5 M NaCl) (21).
When Drosophila S2 extracts were adjusted to 0.5 M NaCl and
then batch bound to phosphocellulose, more than 99% of the
proteins were in the unbound flow-through fraction as meas-
ured using a Bradford assay. Bound proteins were eluted at 1.5
M NaCl and constituted less than 1% of total proteins (data not
shown). Western analysis of the flow-through versus elution
fraction demonstrated that all measurable amounts of dCREB2
and CKI were in the flow-through fraction (data not shown).
CKII was one of the few proteins present in the bound and
eluted fraction. If the S2 kinase resembles CKI, it should be in
the flow-through fraction, whereas if it resembles CKII, it
should be in the elution fraction.
Fig. 8A demonstrates that the S2 kinase is present in the
elution fraction. Lane 1 shows the migration of rec-dCREB2-wt
when assayed by EMSA. Mixing recombinant dCREB2 with
the phosphocellulose flow-through fraction in the presence of
ATP did not inhibit DNA binding (lane 4), while mixing with
elution fraction completely abolished binding (lane 7). This
effect of the elution fraction on binding was reversed by phos-
phatase treatment (lane 8). Endogenous dCREB2 migrated at a
position slightly lower than recombinant dCREB2 and was
present in the flow-through fraction (lane 3). Although the
kinase was not active in the flow-through fraction, endogenous
dCREB2 remained phosphorylated and unable to bind DNA
unless treated with phosphatase (lanes 2 and 3). When the
flow-through fraction was mixed with rec-dCREB2-wt and sub-
sequently treated with phosphatase, both endogenous and re-
combinant dCREB2 were able to bind resulting in a darker,
broader gel shift. This broader gel species contained both re-
combinant and endogenous proteins and possibly species due to
heterodimer-mediated binding.
The observation that the S2 kinase is in the eluted fraction
suggests that it may be related to CKII. To further test this
idea, we determined whether this kinase could use GTP as a
phosphate source. CKI has been shown to strictly require ATP
as a phosphate donor, while CKII can use either ATP or GTP.
In the left panel of Fig. 8B, rec-dCREB2-wt was phosphorylated
using an S2 extract in the presence of either [-32P]ATP or
[-32P]GTP, separated by PAGE, and analyzed using autora-
diography. The S2 kinase activity was able to use either nucle-
otide triphosphate as a phosphate source. As further charac-
terization, we determined whether the S2 kinase was inhibited
by DRB, a potent and specific inhibitor of CKII (6 M DRB
reduces CKII activity 50%) (32, 33). The right panel of Fig. 8B
shows the incorporation of radioactive phosphate into rec-
dCREB2-wt using an S2 extract in the presence of varying
FIG. 5. Effects of CKII phosphorylation on CRE binding of wild
type and mutated recombinant dCREB2. Lanes 1–4 show EMSA of
3 ng of unphosphorylated recombinant dCREB2 proteins. wt refers to
wild type, 133 indicates a mutation converting Ser-231 to Ala, CK
indicates Ser to Ala mutations at the four CK sites, and 142 indicates a
Ser-240 to Ala mutation. In lanes 5–8, the recombinant proteins were
first phosphorylated using CKII prior to EMSA. In lanes 9–12, proteins
were first phosphorylated and then dephosphorylated using  phospha-
tase prior to EMSA.
FIG. 6. EMSA of recombinant dCREB2 treated with Schnei-
der-2 cell extract. EMSA was performed on rec-dCREB2-wt and rec-
dCREB2-CK. Lanes 1 and 2 show gel shifts of 3 ng of the recombinant
proteins alone. Lanes 3 and 4 show gel shifts of the proteins after
incubating them with S2 extract in the presence of ATP. In lanes 5 and
6, proteins were first incubated with S2 extract and ATP and then
subsequently dephosphorylated with excess  phosphatase before being
subjected to EMSA. Note that phosphatase treatment allows both re-
combinant protein and dCREB2 from extracts to bind. Lane 7 shows
EMSA of untreated S2 extract.
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concentrations of DRB. Proteins were incubated in the pres-
ence or absence of drug, separated using PAGE, and visualized
using autoradiography. As seen, 6 M DRB severely inhibited
incorporation, and higher concentrations led to complete inhi-
bition of incorporation. Taken together, these results suggest
that the kinase active in S2 extracts that prevents DNA bind-
ing is CKII.
Transgenic dCREB2-CK Binds CRE Sites in the Absence of
Phosphatase Treatment—All previous experiments demon-
strating the importance of the CK sites for dCREB2 DNA
FIG. 7. Peptide analysis of phosphorylated sites on dCREB2. A, the indicated amounts of rec-dCREB2-wt were phosphorylated using S2
extract or CKII in the presence of [-32P]ATP and analyzed by SDS-PAGE and autoradiography. The position of dCREB2 is marked. B,
rec-dCREB2-wt phosphorylated with [-32P]ATP using the indicated kinases or S2 extract was subjected to SDS-PAGE and autoradiography as in
A. Gel slices containing phosphorylated rec-dCREB2-wt were excised and trypsinized. Resulting peptides were eluted, separated in two dimensions
by electrophoresis and chromatography, and analyzed by autoradiography. A peptide phosphorylated by PKA and CaMKII is labeled “A,” and a
second peptide/peptides phosphorylated by CKI, CKII, and S2 extract is labeled “B.” C, rec-dCREB2-wt and rec-dCREB2-CK were phosphorylated
using S2 extract and subjected to tryptic peptide mapping as in B. The position of peptide “B” is marked. In B and C, all blots were aligned such
that electrophoresis proceeded in the horizontal direction with the cathode to the right. Chromatography was performed in the vertical direction
proceeding upward. Samples were loaded in an equivalent position on each blot, labeled with an “O” on one blot.
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binding involved phosphorylation reactions in vitro. However,
in vitro phosphorylation varies considerably depending on how
much kinase is added, and it is difficult to determine the
appropriate ratio of substrate to kinase to match in vivo con-
ditions. To partially address this problem, we made transgenic
flies carrying mutations in various phosphorylation sites. hs-
CREB-wt refers to a transgenic line expressing dCREB2-b, an
isoform nearly identical to rec-dCREB2-wt used in our in vitro
analysis. hs-CREB-133 expresses the same isoform with a Ser-
231 to Ala mutation, and hs-CREB-CK expresses this isoform
with the CK sites mutated, similar to recombinant rec-
dCREB2-CK. Overexpressed dCREB2 behaved similarly to en-
dogenous protein with respect to DNA binding (Fig. 9, lanes
1–3). Extracts from hs-CREB-wt flies did not show CRE bind-
ing activity, but phosphatase treatment prior to EMSA un-
masked binding. Extracts from hs-CREB-133 flies behaved
identically to hs-CREB-wt fly extracts (lanes 4–7) supporting
the idea that phosphorylation of Ser-231 does not have a major
effect on DNA binding. On the other hand, dCREB2 from
extracts made from hs-CREB-CK flies was able to bind CRE
sites in the absence of phosphatase treatment, and there was
no significant increase in binding activity upon treatment
(lanes 8–11). These results further support the idea that the
four CK sites play a major role in the regulation of DNA
binding by dCREB2. They also suggest, but do not prove, that
phosphorylation of these sites may be occurring in vivo.
dCREB2 Is Likely to Be Phosphorylated at the Casein Kinase
Sites in Vivo—Since we demonstrated that there was an active
kinase in our extracts, it is possible that the phosphorylation
occurred exclusively in vitro after extracts had been made
rather than in vivo. To address this issue, we made Drosophila
head extracts in the presence of 100 mM EDTA, a concentration
that abolishes CKI, CKII, and S2 kinase activity in extracts
(data not shown). These were used in two experiments. In the
first, extracts were adjusted to 0.5 M NaCl and then fraction-
ated using phosphocellulose. Phosphocellulose can be used to
separate dCREB2 from S2 kinase since dCREB2 is found in the
flow-through fraction and the kinase is found in the elution
fraction (Fig. 6A). The flow-through fraction, which no longer
contains kinase, was subsequently dialyzed to physiological
salt and EDTA concentrations and tested for DNA binding.
Indistinguishable from previous experiments, dCREB2 did not
bind in the absence of phosphatase (data not shown), indicating
that phosphorylation of the CK sites most likely occurs in
Drosophila prior to extract preparation.
In a second experiment, high EDTA extracts were compared
with low EDTA extracts that had been either treated or un-
treated with phosphatase in a denaturing non-SDS-PAGE sys-
tem. SDS-PAGE cannot be used to distinguish between phos-
phorylated and dephosphorylated dCREB2 (data not shown).
Since this is likely due to the excess SDS-mediated negative
charge masking any small charge differences due to phospho-
rylation, we replaced SDS with 8 M urea as the denaturant in
our gels and assayed for dCREB2 by Western blotting. As
shown in Fig. 10, when low EDTA extracts from the hs-
CREB-wt line were run on this gel system, a clear difference
was seen in dCREB2 mobility between untreated and phos-
phatase-treated samples (lanes 1 and 2). When hs-CREB-wt
extract was made in high EDTA conditions, dCREB2 migrated
at the same position as non-phosphatase-treated extracts (lane
3), suggesting that dCREB2 exists in a phosphorylated state
FIG. 8. Analysis of the kinase active in Schneider-2 cell ex-
tracts. A, S2 extracts were separated, using phosphocellulose, into two
fractions, a PCell flow-through, which does not bind to phosphocellulose
at 0.5 M NaCl, and a PCell elution, which binds at 0.5 M and elutes at
1.5 M NaCl. To identify which fraction contains the S2 kinase, fractions
were mixed with rec-dCREB2-wt and assayed by EMSA. Lanes 1, 2, and
6 show the gel shifts of unmixed rec-dCREB2-wt, PCell flow-through,
and PCell elution, respectively. Lanes 4 and 7 show gel shifts of
dCREB2-wt after being mixed with PCell flow-through and PCell elu-
tion, respectively. Lanes 5 and 8 show shifts after mixing and subse-
quent phosphatase treatment. Lane 3 identifies the gel shift of endog-
enous dCREB2, which is in the PCell flow-through and adds
background bands to lane 5. In this panel, all lanes are from the same
autoradiogram, and irrelevant lanes were removed for clarity. B, rec-
dCREB2-wt was phosphorylated in vitro by mixing with S2 extract in
the presence of either [-32P]ATP or [-32P]GTP. Phosphorylation reac-
tions were subjected to SDS-PAGE, and phosphate incorporation into
rec-dCREB2-wt was analyzed by autoradiography. C, rec-dCREB2-wt
was phosphorylated using S2 extract in the presence of [-32P]ATP and
various concentrations of the CKII inhibitor DRB. Incorporation of
phosphate into CREB-wt was analyzed by SDS-PAGE followed by
autoradiography.
FIG. 9. CRE binding of transgenic dCREB2. Transgenic flies that
overexpress wild type and mutated forms of dCREB2 under control of a
heat shock promoter were generated as described under “Materials and
Methods.” hs-CREB-wt expresses a wild type repressor isoform of
dCREB2, hs-CREB-133 expresses a Ser-231 to Ala mutated form, and
hs-CREB-CK expresses a dCREB2 with the four CK sites mutated to
Ala. Transgenes were induced by heat shocking at 37 °C for 30 min. 3 h
after heat shock, flies were harvested, and head extracts were made.
EMSA was performed on 5 g of extract. Assays were performed either
in the absence or presence of  phosphatase as indicated. Supershifts
using dCREB2 monoclonal antibody are also indicated. mAb, mono-
clonal antibody.
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prior to extract preparation. To determine whether this in vivo
phosphorylation occurs at the CK sites, extracts were made
from hs-CREB-CK lines, and migration of dCREB2 was com-
pared with that of wild type. As shown in lanes 4–6, dCREB2
mutated at the CK sites migrated close to the same position as
dephosphorylated dCREB2 and separate from non-phospha-
tase-treated dCREB2, indicating that the faster migrating
form of dCREB2 is due in large part to CK site phosphoryla-
tion. We attribute the slight difference in mobility between
CREB-CK and dephosphorylated dCREB2 or CREB-CK (the
bands in lanes 4 and 6 migrate slightly farther than those in
lanes 2 and 5) to phosphorylation occurring at Ser-231. These
results indicate that dCREB2 is likely to exist in Drosophila in
a form where the CK sites are phosphorylated.
DISCUSSION
The importance of Ser-133 phosphorylation in CREB activa-
tion has been well characterized and is a conserved require-
ment between mammalian and Drosophila CREB proteins (1,
12, 19). However, Ser-133 phosphorylation alone may not be
sufficient for CREB activation (34). In a number of cases,
stimuli that induce Ser-133 phosphorylation do not completely
parallel CREB-dependent transcription (35), and the prepon-
derance of conserved phosphorylation sites between CREB pro-
teins from different species suggests that other sites may play
important roles in regulation. Recent reports have begun to
elucidate the role of these sites.
However, it has been difficult in mammalian systems to
unambiguously define a regulatory role for these other sites.
Ser-129 has been reported to decrease CREB DNA binding
when phosphorylated (16), but phosphorylation of Ser-142 has
been reported both to increase activity and decrease activity
(17, 18, 36). In addition, phosphorylation of the CK sites has
been reported to increase DNA binding of CREM (24) but have
no effect on binding for mammalian CREB (15). We have uti-
lized Drosophila CREB to try to clarify some of these
discrepancies.
Similarities between Drosophila and mammalian CREB are
indicated by the conservation of Ser-133/231 and other sites
within the KID (1, 20). However, there seem to be differences in
the relative importance and usage of different regulatory path-
ways in regulating CREB activity. In mammals, most CREB
exists with Ser-133 in a dephosphorylated state, and phospho-
rylation of this site is a crucial step in CREB activation (37). In
Drosophila, we showed that a large proportion of dCREB2 was
already phosphorylated at Ser-231, indicating that regulation
by increasing Ser-231 phosphorylation may be less important
than regulation by other means. In a second, Ser-231-inde-
pendent regulatory step that we present here, we demon-
strated that dCREB2 was completely unable to bind CRE sites
unless first dephosphorylated at sites other than Ser-231. Pre-
liminary results in mammalian extracts suggests that this step
is conserved on mammalian CREB for at least a fraction of the
detectable protein (data not shown). These results suggest a
conserved mechanism of CREB regulation, although in this
case the pathway is more tightly regulated in Drosophila than
in mammals. The tight on/off type regulation of dCREB2 bind-
ing allowed us to unambiguously identify the CK sites as im-
portant for this effect. In addition, we showed that Drosophila
CKII was likely to phosphorylate these sites and these sites
were likely to exist in a phosphorylated state in vivo.
Although we identified four CK sites on dCREB2 that play
significant roles in altering DNA binding, it is not absolutely
certain that phosphorylation of all four sites is necessary to
inhibit binding. Possibly phosphorylation of only a subset of
these sites is adequate. Indeed, in our peptide mapping exper-
iments, peptide B, which was phosphorylated by CKI, CKII and
the S2 kinase, seems to consist of several closely spaced spots
that may reflect differentially phosphorylated species. In addi-
tion, although the four sites are clearly important, we cannot
dismiss the possibility that there is another site or sites that
also contribute to regulating DNA binding. In our peptide map-
ping experiments, the phosphopeptide pattern for CREB phos-
phorylated by CKII included many peptides unrelated to the
one containing the CK sites. However, purified recombinant
CKII is an extremely active enzyme that phosphorylates many
sites in vitro that are not necessarily phosphorylated in vivo.
Upon dilution of recombinant CKII, we obtained phosphopep-
tide patterns that resembled the pattern obtained when CREB
was phosphorylated using CKI or S2 kinase. The excess enzy-
matic activity of recombinant CKII can also be used to explain
a possible slight reduction of binding of CREB-CK upon CKII
treatment seen in Figs. 5 and 6. We suspect that we identified
the relevant sites for the following reasons. In our peptide
mapping experiments, peptide B seemed to be the major spe-
cies phosphorylated by the S2 kinase. Also, in hs-CREB-CK
flies, dCREB2 bound extremely well in the absence of phospha-
tase, and the addition of phosphatase did not significantly
increase binding. Finally, in our urea PAGE experiments,
CREB-CK ran at a position very similar to dephosphorylated
CREB. A slight mobility change between CREB-CK and de-
phosphorylated CREB is likely to be due to phosphorylation of
Ser-133/231, which is normally phosphorylated in Drosophila.
Our data on Drosophila CREB showed an inhibitory effect of
phosphorylation on binding. However, previously published re-
ports on the modulation of CREB DNA binding are inconsistent
with our results. Bullock and Habener (15) have shown that
phosphorylation of the casein kinase sites has little effect on
CREB binding affinity, although they found that having acidic
amino acids next to these sites affects CREB binding affinity.
De Groot et al. (24) report an increase in DNA binding upon
phosphorylation of these sites on CREM. It is unclear what
factors, such as species differences or experimental conditions,
are responsible for these differences. In our studies, we have
focused on binding to high affinity symmetric CRE sites origi-
nally found in the somatostatin promoter region (12). Binding
of CREB to lower affinity non-symmetric sites may be regu-
lated differently (38, 39). Additionally alterations in CKII ac-
tivity due to cell division cycle and due to redox state may
further complicate matters (40, 41).
Our results demonstrated that the CK sites were phospho-
FIG. 10. Analysis of transgenic dCREB2 using a denaturing
non-SDS-PAGE system. Transgenic dCREB2 protein was induced in
hs-CREB-wt and hs-CREB-CK flies as described in Fig. 9. Head ex-
tracts were made in buffer containing either 0.1 mM EDTA or 100 mM
EDTA (high EDTA). Extracts made in low EDTA were either treated
with  phosphatase or left untreated. Samples were separated on a
PAGE system lacking SDS and containing 8 M urea to observe mobility
differences between different phosphorylated forms of dCREB2.
dCREB2 was identified by Western blotting.
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rylated in extracts and are likely to be phosphorylated in vivo.
The development of phospho- and dephosphospecific antibodies
will be needed to demonstrate this unequivocally. Since CREB
activity requires both DNA binding and transcriptional activa-
tion, it is likely that the active form of CREB is dephosphoryl-
ated, or otherwise modified, at the CK sites and phosphoryl-
ated at Ser-231. We should note, however, that we have not yet
identified this species of CREB in wild type extracts, and it will
be of great interest to determine how this form is generated.
Many groups have observed that stimuli able to produce
CRE-dependent gene expression consist of only those able to
induce a particularly long lasting Ser-133 phosphorylation (34,
35, 42). It is possible that the complex regulation of CREB may
explain this requirement for sustained phosphorylation, and
this requirement has interesting implications about CREB in
memory formation. In Drosophila, long term memory forma-
tion, which is dCREB2-dependent, requires multiple training
trials with rest intervals between the individual trials (spaced
training) (43, 44). Equal numbers of massed trials, where there
are no interspersed rest intervals, do not produce long term
memory. Our current results suggest several intriguing possi-
bilities regarding these temporal requirements for CREB acti-
vation. We propose that inactive dCREB2 exists in flies in a
state where both the CK sites and Ser-231 are phosphorylated.
In one model, activation of dCREB2 may occur through an
induction of a phosphatase that dephosphorylates the CK sites
specifically. This would result in a relatively simple one-step
activation of dCREB2. However, sequence-specific selectivity
in serine phosphatases has not been demonstrated in general,
suggesting a second possibility. In this second model, activation
of dCREB2 results from induction of a phosphatase that de-
phosphorylates both Ser-231 and the CK sites. Dephosphoryl-
ated dCREB2 is able to bind DNA but requires the subsequent
activity of a Ser-231 kinase to become fully active. Following
activation, CKII or a related kinase can inactivate dCREB2 by
phosphorylating the CK sites. Thus, dCREB2 activation would
require two sequential steps, a nonspecific dephosphorylation
step followed by at least one specific phosphorylation step. The
duration of dCREB2 activation would depend on the longevity of
Ser-231 phosphorylation and the kinetics of CK site phosphoryl-
ation. Thus it is possible that dCREB2 activation would require
inhibition of CKII as well as activation of a phosphatase.
This model predicts that continued activation of dCREB2
may be partially counterproductive since induction of the phos-
phatase may dephosphorylate Ser-231 and other residues
whose phosphorylation are required for transcriptional activ-
ity. This suggests that maximal induction of dCREB2 may
require phasic induction, which might explain the efficacy of
spaced training. Studies on the role of the signal transduction
pathways that regulate casein kinase activity or the activity of
a putative endogenous phosphatase that would dephosphoryl-
ate the CK sites will be of great interest in the future.
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